Quantcast
Last updated on April 23, 2014 at 17:08 EDT

Latest Vatera Healthcare Partners LLC Stories

2011-12-13 06:00:00

CAMBRIDGE, Mass., Dec. 13, 2011 /PRNewswire/ -- ImmusanT, Inc. announced today it has raised $20 million in Series A financing from Vatera Healthcare Partners LLC to advance development of the biotechnology company's immunotherapeutic vaccine Nexvax2®, companion diagnostic and monitoring tool for celiac disease. The proceeds will fund the Nexvax2 therapeutic and diagnostic development plan to the point of demonstrating proof-of-concept. ImmusanT expects to initiate...